Mon, Jul 22, 2024
Volume 9, Issue 3 (Summer 2023)
Caspian J Neurol Sci 2023, 9(3): 143-153 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Safarionpur K, Zebardast A, Saberi A. Effectiveness of Behavior Management Intervention in Migraine With a Focus on Comorbid Depressive Symptoms. Caspian J Neurol Sci 2023; 9 (3) :143-153
URL: http://cjns.gums.ac.ir/article-1-638-en.html
URL: http://cjns.gums.ac.ir/article-1-638-en.html
1- Department of Psychology, Faculty of Literature and Humanities, University of Guilan, Rasht, Iran.
2- Department of Neurology, Faculty of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
2- Department of Neurology, Faculty of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
Abstract: (756 Views)
Background: Migraine negatively affects sufferers’ physical and mental health and social and
economic status.
Objectives: This study compared the effectiveness of behavior management therapy and
pharmacotherapy in reducing migraine-related disabilities with and without focusing on comorbid
depressive symptoms.
Materials & Methods: This quasi-experimental study has a pre-test-post-test design with a control
group. The study was conducted on migrainous patients with comorbid depressive symptoms
referred to neurology clinics in Rasht City, Iran, in 2021. A total of 18 female patients were selected
using purposive sampling based on neurological diagnosis and the diagnostic and statistical manual
of mental disorders (DSM-5) criteria for depressive disorder. The participants were randomly
assigned to two groups after matching regarding age and severity of depression. Combined therapy
(behavior management intervention [BM] and pharmacotherapy [P]) was performed in two
groups during eight sessions, with (case group) and without (control group) focusing on comorbid
depressive symptoms. The data were collected using the Beck depression inventory (BDI-II), the
headache disability inventory (HDI) , and the headache diary (HD) and analyzed using multivariate
analysis of covariance.
Results: The first therapeutic approach was significantly superior to the second in reducing
migraine-related disabilities (F(2, 13)=10.43, P<0.05, Wilks Lambda=0.384, partial Ƞ2=0.616).
Conclusion: Combined therapy (BM & P) focusing on comorbid depressive symptoms can be an
alternative or complementary therapeutic method to reduce various disabilities in migraine patients.
economic status.
Objectives: This study compared the effectiveness of behavior management therapy and
pharmacotherapy in reducing migraine-related disabilities with and without focusing on comorbid
depressive symptoms.
Materials & Methods: This quasi-experimental study has a pre-test-post-test design with a control
group. The study was conducted on migrainous patients with comorbid depressive symptoms
referred to neurology clinics in Rasht City, Iran, in 2021. A total of 18 female patients were selected
using purposive sampling based on neurological diagnosis and the diagnostic and statistical manual
of mental disorders (DSM-5) criteria for depressive disorder. The participants were randomly
assigned to two groups after matching regarding age and severity of depression. Combined therapy
(behavior management intervention [BM] and pharmacotherapy [P]) was performed in two
groups during eight sessions, with (case group) and without (control group) focusing on comorbid
depressive symptoms. The data were collected using the Beck depression inventory (BDI-II), the
headache disability inventory (HDI) , and the headache diary (HD) and analyzed using multivariate
analysis of covariance.
Results: The first therapeutic approach was significantly superior to the second in reducing
migraine-related disabilities (F(2, 13)=10.43, P<0.05, Wilks Lambda=0.384, partial Ƞ2=0.616).
Conclusion: Combined therapy (BM & P) focusing on comorbid depressive symptoms can be an
alternative or complementary therapeutic method to reduce various disabilities in migraine patients.
Type of Study: Research |
Subject:
Special
Received: 2023/07/5 | Accepted: 2023/07/28 | Published: 2023/07/28
Received: 2023/07/5 | Accepted: 2023/07/28 | Published: 2023/07/28
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
